U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Glimepiride response

MedGen UID:
1105342
•Concept ID:
CN437678
•
Sign or Symptom
Drug:
Glimepiride
MedGen UID:
16604
•Concept ID:
C0061323
•
Pharmacologic Substance
A long-acting, third-generation sulfonylurea with hypoglycemic activity. Compared to other generations of sulfonylurea compounds, glimepiride is very potent and has a longer duration of action. This agent is metabolized by CYP2C9 and shows peroxisome proliferator-activated receptor gamma (PPARgamma) agonistic activity. [from NCI]
Glimepiride
 
Gene (location): G6PD (Xq28)

Professional guidelines

PubMed

Comparative effectiveness of multiple different treatment regimens for nonalcoholic fatty liver disease with type 2 diabetes mellitus: a systematic review and Bayesian network meta-analysis of randomised controlled trials.
Deng M, Wen Y, Yan J, Fan Y, Wang Z, Zhang R, Ren L, Ba Y, Wang H, Lu Q, Fan H
BMC Med 2023 Nov 16;21(1):447. doi: 10.1186/s12916-023-03129-6. PMID: 37974258Free PMC Article
Evaluating gliclazide for the treatment of type 2 diabetes mellitus.
Tomlinson B, Li YH, Chan P
Expert Opin Pharmacother 2022 Dec;23(17):1869-1877. Epub 2022 Nov 10 doi: 10.1080/14656566.2022.2141108. PMID: 36300277
The role of glimepiride in the treatment of type 2 diabetes mellitus.
Briscoe VJ, Griffith ML, Davis SN
Expert Opin Drug Metab Toxicol 2010 Feb;6(2):225-35. doi: 10.1517/17425250903512955. PMID: 20055691

Curated

Gammal et al, Expanded Clinical Pharmacogenetics Implementation Consortium Guideline for Medication Use in the Context of G6PD Genotype. 2 Sept 2022. Clin Pharmacol Ther.

Recent clinical studies

Etiology

Impact of Insulin Sensitivity and β-Cell Function Over Time on Glycemic Outcomes in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE): Differential Treatment Effects of Dual Therapy.
Utzschneider KM, Younes N, Butera NM, Balasubramanyam A, Bergenstal RM, Barzilay J, DeSouza C, DeFronzo RA, Elasy T, Krakoff J, Kahn SE, Rasouli N, Valencia WM, Sivitz WI; GRADE Research Group
Diabetes Care 2024 Apr 1;47(4):571-579. doi: 10.2337/dc23-1059. PMID: 38190619Free PMC Article
Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial.
Ridderstråle M, Andersen KR, Zeller C, Kim G, Woerle HJ, Broedl UC; EMPA-REG H2H-SU trial investigators
Lancet Diabetes Endocrinol 2014 Sep;2(9):691-700. Epub 2014 Jun 16 doi: 10.1016/S2213-8587(14)70120-2. PMID: 24948511
Glucose control and vascular complications in veterans with type 2 diabetes.
Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD; VADT Investigators
N Engl J Med 2009 Jan 8;360(2):129-39. Epub 2008 Dec 17 doi: 10.1056/NEJMoa0808431. PMID: 19092145
Rosiglitazone and glimeperide: review of clinical results supporting a fixed dose combination.
Pfützner A, Wilhelm B, Forst T
Vasc Health Risk Manag 2007;3(2):211-20. doi: 10.2147/vhrm.2007.3.2.211. PMID: 17580731Free PMC Article
Clinical review of glimepiride.
McCall AL
Expert Opin Pharmacother 2001 Apr;2(4):699-713. doi: 10.1517/14656566.2.4.699. PMID: 11336617

Diagnosis

Impact of Insulin Sensitivity and β-Cell Function Over Time on Glycemic Outcomes in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE): Differential Treatment Effects of Dual Therapy.
Utzschneider KM, Younes N, Butera NM, Balasubramanyam A, Bergenstal RM, Barzilay J, DeSouza C, DeFronzo RA, Elasy T, Krakoff J, Kahn SE, Rasouli N, Valencia WM, Sivitz WI; GRADE Research Group
Diabetes Care 2024 Apr 1;47(4):571-579. doi: 10.2337/dc23-1059. PMID: 38190619Free PMC Article
Adiponectin: a manifold therapeutic target for metabolic syndrome, diabetes, and coronary disease?
Fisman EZ, Tenenbaum A
Cardiovasc Diabetol 2014 Jun 23;13:103. doi: 10.1186/1475-2840-13-103. PMID: 24957699Free PMC Article
Glucose control and vascular complications in veterans with type 2 diabetes.
Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD; VADT Investigators
N Engl J Med 2009 Jan 8;360(2):129-39. Epub 2008 Dec 17 doi: 10.1056/NEJMoa0808431. PMID: 19092145
The role of sulphonylureas in the management of type 2 diabetes mellitus.
Rendell M
Drugs 2004;64(12):1339-58. doi: 10.2165/00003495-200464120-00006. PMID: 15200348
Clinical review of glimepiride.
McCall AL
Expert Opin Pharmacother 2001 Apr;2(4):699-713. doi: 10.1517/14656566.2.4.699. PMID: 11336617

Therapy

Pharmacogenetic-guided glimepiride therapy in type-2 diabetes mellitus: a cost-effectiveness study.
Fokoun C, Serrier H, Rabier H, Goutelle S, Tod M, Bourguignon L
Pharmacogenomics J 2021 Oct;21(5):559-565. Epub 2021 Mar 17 doi: 10.1038/s41397-021-00232-w. PMID: 33731883
Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial.
Ridderstråle M, Andersen KR, Zeller C, Kim G, Woerle HJ, Broedl UC; EMPA-REG H2H-SU trial investigators
Lancet Diabetes Endocrinol 2014 Sep;2(9):691-700. Epub 2014 Jun 16 doi: 10.1016/S2213-8587(14)70120-2. PMID: 24948511
Glucose control and vascular complications in veterans with type 2 diabetes.
Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD; VADT Investigators
N Engl J Med 2009 Jan 8;360(2):129-39. Epub 2008 Dec 17 doi: 10.1056/NEJMoa0808431. PMID: 19092145
Clinical review of glimepiride.
McCall AL
Expert Opin Pharmacother 2001 Apr;2(4):699-713. doi: 10.1517/14656566.2.4.699. PMID: 11336617
Glimepiride. A review of its use in the management of type 2 diabetes mellitus.
Langtry HD, Balfour JA
Drugs 1998 Apr;55(4):563-84. doi: 10.2165/00003495-199855040-00007. PMID: 9561345

Prognosis

The efficacy of canagliflozin in diabetes subgroups stratified by data-driven clustering or a supervised machine learning method: a post hoc analysis of canagliflozin clinical trial data.
Zou X, Huang Q, Luo Y, Ren Q, Han X, Zhou X, Ji L
Diabetologia 2022 Sep;65(9):1424-1435. Epub 2022 Jul 8 doi: 10.1007/s00125-022-05748-9. PMID: 35802168
Multi-objective optimization strategy based on desirability functions used for electrophoratic separation and quantification of rosiglitazone and glimepiride in plasma and formulations.
Hefnawy MM, Sultan MA, Al-Johar HI, Kassem MG, Aboul-Enein HY
Drug Test Anal 2012 Jan;4(1):39-47. Epub 2011 Mar 18 doi: 10.1002/dta.260. PMID: 21416633
Population pharmacokinetic analysis of glimepiride with CYP2C9 genetic polymorphism in healthy Korean subjects.
Yoo HD, Kim MS, Cho HY, Lee YB
Eur J Clin Pharmacol 2011 Sep;67(9):889-98. Epub 2011 Apr 8 doi: 10.1007/s00228-011-1035-2. PMID: 21476064
Glucose control and vascular complications in veterans with type 2 diabetes.
Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD; VADT Investigators
N Engl J Med 2009 Jan 8;360(2):129-39. Epub 2008 Dec 17 doi: 10.1056/NEJMoa0808431. PMID: 19092145
Combining sulfonylureas and other oral agents.
Riddle M
Am J Med 2000 Apr 17;108 Suppl 6a:15S-22S. doi: 10.1016/s0002-9343(00)00338-7. PMID: 10764846

Clinical prediction guides

Pairing 3D-Printing with Nanotechnology to Manage Metabolic Syndrome.
El-Say KM, Felimban RI, Tayeb HH, Chaudhary AG, Omar AM, Rizg WY, Alnadwi FH, Abd-Allah FI, Ahmed TA
Int J Nanomedicine 2022;17:1783-1801. Epub 2022 Apr 21 doi: 10.2147/IJN.S357356. PMID: 35479768Free PMC Article
Metabolic Interaction Potential between Clopidogrel and Sulfonylurea Antidiabetic Agents: Effects on Clopidogrel Bioactivation.
Shao H, Lu J, Xu YT, Zhan Y, Chen GM, Zhang HJ
Pharmacology 2016;97(1-2):18-24. Epub 2015 Nov 17 doi: 10.1159/000441230. PMID: 26569597
Fasiglifam as a new potential treatment option for patients with type 2 diabetes.
Kaku K
Expert Opin Pharmacother 2013 Dec;14(18):2591-600. Epub 2013 Nov 6 doi: 10.1517/14656566.2013.851668. PMID: 24195772
Liraglutide: a once-daily incretin mimetic for the treatment of type 2 diabetes mellitus.
Neumiller JJ, Campbell RK
Ann Pharmacother 2009 Sep;43(9):1433-44. Epub 2009 Jul 28 doi: 10.1345/aph.1M134. PMID: 19638470
Glucose control and vascular complications in veterans with type 2 diabetes.
Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD; VADT Investigators
N Engl J Med 2009 Jan 8;360(2):129-39. Epub 2008 Dec 17 doi: 10.1056/NEJMoa0808431. PMID: 19092145

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Curated

    • CPIC, 2022
      Gammal et al, Expanded Clinical Pharmacogenetics Implementation Consortium Guideline for Medication Use in the Context of G6PD Genotype. 2 Sept 2022. Clin Pharmacol Ther.

    Consumer resources

    Reviews

    Related information

    • Gene
      Related information in NCBI Gene
    • GTR
      Related information in GTR
    • GTR(Clinical)
      Clinical tests in GTR
    • OMIM(Genes)
      OMIM records containing genes associated with phenotypes registered in MedGen
    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...